Bausch + Lomb (US:BLCO)2024-07-31 20:44Financial Performance - Bausch + Lomb reported a strong Q2 2024 performance with revenue growth of 17% to $1.216 billion compared to $1.035 billion in Q2 2023[10, 14] - Constant Currency (CC) revenue growth was even stronger at +20% compared to Q2 2023[8, 10] - Adjusted Gross Profit increased by 22% to $753 million, with an Adjusted Gross Margin of 61.9%, a 220 bps increase year-over-year[16] - The company is raising its FY24 revenue guidance to $4.7 - $4.8 billion and CC revenue growth to ~16-18%[20] - Adjusted EBITDA guidance is also raised to $850 - $900 million[20] Segment Performance - All segments contributed to the growth, with Pharmaceuticals leading at +61% CC revenue growth[11] - Vision Care segment revenue grew by 11% CC, Surgical by 9% CC[11] Key Growth Drivers - The Daily SiHy portfolio experienced significant growth, with a +67% increase in Q2 2024 revenue[24] - OTC Dry Eye Portfolio grew +24%[25]